ArticleArthritis care & research2018
Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
Article in Arthritis care & research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.Rheumatology (Oxford, England) · 2023Trial
- Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis.RMD open · 2022Trial
- A narrative review on radiographic progression to monitor psoriatic arthritis activity.Advances in rheumatology (London, England) · 2026Review
- Early and Mid-Term Ultrasound Response to Guselkumab in Psoriatic Arthritis: A Real-World Cohort from a Single Tertiary Rheumatology Center.Journal of clinical medicine · 2026Article
- Tildrakizumab as a Potential Option for Early Psoriatic Arthritis in Patients with Metabolic Comorbidities and Psoriasis: a Case Series.Dermatology practical & conceptual · 2025Article
- Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort.RMD open · 2024Article
- Telemedicine in Nail Psoriasis: Validation of a New Tool to Monitor (In-Person, In-Picture, and In-Video) Nail Psoriasis Severity in Patients with Concurrent Onychophagia and Onychotillomania.Dermatology and therapy · 2024Article
- Patients with longstanding pPatients with longstanding psoriatic arthritis can achieve DAPSA remission or low disease activity and it correlates to better functional outcomes: results from a Latin-American real-life cohort.Advances in rheumatology (London, England) · 2024Article
- MRI Findings in Axial Psoriatic Spondylarthritis.Diagnostics (Basel, Switzerland) · 2023Review
- Importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis.RMD open · 2022Article
- Residual Disease in Patients with Axial Spondyloarthritis: A Post-Hoc Analysis of the QUASAR Study.Journal of clinical medicine · 2022Article
- Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence.Rheumatology and therapy · 2022Review
- Correlation of patient-reported routine assessment of patient index data with clinical measures of disease activity in psoriatic arthritis.International journal of rheumatic diseases · 2022Article
- Characterizing memory T helper cells in patients with psoriasis, subclinical, or early psoriatic arthritis using a machine learning algorithm.Arthritis research & therapy · 2022Article
- Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study.Therapeutic advances in musculoskeletal disease · 2021Article
- Measuring Outcomes in Psoriatic Arthritis.Arthritis care & research · 2020Review
- Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis.RMD open · 2020Article
- Assessment of the many faces of PsA: single and composite measures in PsA clinical trials.Rheumatology (Oxford, England) · 2020Review
- Progressive structural bone changes and their relationship with treatment in patients with psoriatic arthritis: a longitudinal HR-pQCT study.Arthritis research & therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTreat-to-target strategies have improved outcomes in rheumatic diseases. In psoriatic arthritis (PsA), the proposed targets are the multidimensional target minimal disease activity (MDA) and the articular target Disease Activity index for PsA (DAPSA). The aim of this study was to compare the disease burden of PsA in patients with low disease activity according to the 2 definitions, MDA and DAPSA low disease activity (DAPSA-LDA), 1 year after diagnosis.
methodsWe obtained data on MDA, DAPSA-LDA and disease burden 1 year after diagnosis for patients included in the Dutch southwest early PsA cohort. Disease burden was assessed in 2 domains: "Body functions," including the Short Form 36 bodily pain (SF-36 BP) measure, and "Activity," including the Health Assessment Questionnaire (HAQ).
resultsAmong the 292 patients included, 48% achieved MDA and 74% achieved DAPSA-LDA. Average scores for Body functions and Activity were better in patients who achieved MDA and those who achieved DAPSA-LDA. The scores were significantly better in the 46% of patients who achieved both MDA and DAPSA-LDA than in the 29% of patients who achieved only DAPSA-LDA. The average SF-36 BP score was higher in patients achieving both targets (73.8; 95% confidence interval [95% CI] 71.1-76.5) than in patients achieving only DAPSA-LDA (57.6; 95% CI 54.5-60.8). Similarly, mean HAQ scores measuring Activity were 0.21 (95% CI 0.15-0.26) and 0.63 (95% CI 0.53-0.72), respectively.
conclusionAmong patients with newly diagnosed PsA, 48% achieved MDA and 74% achieved DAPSA-LDA after 1 year of receiving usual care. The average disease burden was better in patients who achieved MDA and those who achieved DAPSA-LDA. Also, patients who achieved only DAPSA-LDA reported worse outcomes than those who also achieved MDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.